Foghorn Therapeutics Inc.
FHTX
$3.87
$0.164.31%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 6.36% | 14.24% | 20.94% | 12.78% | 13.46% |
| Total Depreciation and Amortization | -11.86% | 6.79% | 2.49% | -5.09% | -9.19% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 11.18% | 10.63% | -26.08% | -36.77% | -18.17% |
| Change in Net Operating Assets | 3.89% | 0.39% | 1.01% | 33.50% | 27.55% |
| Cash from Operations | 8.03% | 14.25% | 14.58% | 17.46% | 18.27% |
| Capital Expenditure | 97.36% | 94.48% | -14.01% | -253.59% | -20.90% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 342.64% | 486.54% | 947.88% | -70.59% | -118.75% |
| Cash from Investing | 335.23% | 474.67% | 917.68% | -71.49% | -119.43% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -51.45% | -99.04% | -99.58% | -98.27% | 3,592.75% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 45.98% | -- | 100.00% | -100.00% | -- |
| Cash from Financing | -51.48% | -99.03% | -99.58% | -98.63% | 3,572.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 254.60% | 208.37% | 362.89% | -179.80% | -163.70% |